- 現金殖利率: 5.22%、總殖利率: 5.22%、5年平均現金配發率: 89.44%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | 2.71 | 0.37 | 2.73 | 30.0 | 0.00 | 0 | 100.74 | 29.52 | 0.00 | 0 | 100.74 | 29.52 |
| 2022 (9) | 2.70 | 46.74 | 2.10 | 31.25 | 0.00 | 0 | 77.78 | -10.56 | 0.00 | 0 | 77.78 | -10.56 |
| 2021 (8) | 1.84 | 14.29 | 1.60 | 14.29 | 0.00 | 0 | 86.96 | 0.0 | 0.00 | 0 | 86.96 | 0.0 |
| 2020 (7) | 1.61 | 69.47 | 1.40 | 55.56 | 0.00 | 0 | 86.96 | -8.21 | 0.00 | 0 | 86.96 | -8.21 |
| 2019 (6) | 0.95 | 4650.0 | 0.90 | 0 | 0.00 | 0 | 94.74 | 0 | 0.00 | 0 | 94.74 | 0 |
| 2018 (5) | 0.02 | 0.0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (4) | 0.02 | -80.0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | 0.10 | -79.17 | 0.12 | -72.09 | 0.00 | 0 | 120.00 | 33.95 | 0.00 | 0 | 120.00 | 33.95 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 23Q4 (20) | 0.12 | -91.11 | -67.57 | 0.38 | -11.63 | 5.56 | 2.74 | 2.24 | 0.37 |
| 23Q3 (19) | 1.35 | 84.93 | 107.69 | 0.43 | 19.44 | 59.26 | 2.68 | 106.15 | 13.56 |
| 23Q2 (18) | 0.73 | 28.07 | -37.61 | 0.36 | -12.2 | -23.4 | 1.30 | 128.07 | -23.98 |
| 23Q1 (17) | 0.57 | 54.05 | 5.56 | 0.41 | 13.89 | 32.26 | 0.57 | -79.12 | 5.56 |
| 22Q4 (16) | 0.37 | -43.08 | -54.32 | 0.36 | 33.33 | 176.92 | 2.73 | 15.68 | 46.77 |
| 22Q3 (15) | 0.65 | -44.44 | 62.5 | 0.27 | -42.55 | -12.9 | 2.36 | 38.01 | 124.76 |
| 22Q2 (14) | 1.17 | 116.67 | 485.0 | 0.47 | 51.61 | 51.61 | 1.71 | 216.67 | 167.19 |
| 22Q1 (13) | 0.54 | -33.33 | 22.73 | 0.31 | 138.46 | -22.5 | 0.54 | -70.97 | 22.73 |
| 21Q4 (12) | 0.81 | 102.5 | 107.69 | 0.13 | -58.06 | -69.77 | 1.86 | 77.14 | 14.11 |
| 21Q3 (11) | 0.40 | 100.0 | -32.2 | 0.31 | 0.0 | 0.0 | 1.05 | 64.06 | -14.63 |
| 21Q2 (10) | 0.20 | -54.55 | -42.86 | 0.31 | -22.5 | -13.89 | 0.64 | 45.45 | 0.0 |
| 21Q1 (9) | 0.44 | 12.82 | 46.67 | 0.40 | -6.98 | 60.0 | 0.44 | -73.01 | 46.67 |
| 20Q4 (8) | 0.39 | -33.9 | 21.88 | 0.43 | 38.71 | 4.88 | 1.63 | 32.52 | 69.79 |
| 20Q3 (7) | 0.59 | 68.57 | 78.79 | 0.31 | -13.89 | -24.39 | 1.23 | 92.19 | 95.24 |
| 20Q2 (6) | 0.35 | 16.67 | 84.21 | 0.36 | 44.0 | 227.27 | 0.64 | 113.33 | 113.33 |
| 20Q1 (5) | 0.30 | -6.25 | 172.73 | 0.25 | -39.02 | 1150.0 | 0.30 | -68.75 | 172.73 |
| 19Q4 (4) | 0.32 | -3.03 | 0.0 | 0.41 | 0.0 | 0.0 | 0.96 | 52.38 | 0.0 |
| 19Q3 (3) | 0.33 | 73.68 | 0.0 | 0.41 | 272.73 | 0.0 | 0.63 | 110.0 | 0.0 |
| 19Q2 (2) | 0.19 | 72.73 | 0.0 | 0.11 | 450.0 | 0.0 | 0.30 | 172.73 | 0.0 |
| 19Q1 (1) | 0.11 | 0.0 | 0.0 | 0.02 | 0.0 | 0.0 | 0.11 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/3 | 2.45 | 14.18 | 37.52 | 7.0 | 28.82 | 7.0 | N/A | - | ||
| 2024/2 | 2.14 | -11.04 | 24.63 | 4.56 | 24.59 | 6.64 | N/A | - | ||
| 2024/1 | 2.41 | 15.37 | 24.56 | 2.41 | 24.56 | 6.56 | N/A | - | ||
| 2023/12 | 2.09 | 1.26 | 27.04 | 22.63 | -8.58 | 6.19 | 0.56 | - | ||
| 2023/11 | 2.06 | 1.38 | 26.12 | 20.54 | -11.11 | 6.13 | 0.57 | - | ||
| 2023/10 | 2.04 | 0.38 | 26.44 | 18.48 | -13.95 | 5.99 | 0.58 | - | ||
| 2023/9 | 2.03 | 5.35 | 33.05 | 16.44 | -17.22 | 5.9 | 0.3 | - | ||
| 2023/8 | 1.92 | -1.3 | 26.55 | 14.42 | -21.4 | 5.6 | 0.32 | - | ||
| 2023/7 | 1.95 | 13.29 | 27.21 | 12.49 | -25.74 | 5.43 | 0.33 | - | ||
| 2023/6 | 1.72 | -2.1 | -4.88 | 10.54 | -31.05 | 5.11 | 0.37 | - | ||
| 2023/5 | 1.76 | 8.12 | -54.83 | 8.82 | -34.56 | 5.16 | 0.37 | 主要係子公司業績較去年同期減少，因去年同期正逢國內疫情延燒，子公司搶進快篩試劑通路，帶動去年當期業績大幅成長。 | ||
| 2023/4 | 1.63 | -8.67 | -11.63 | 7.06 | -26.33 | 5.13 | 0.37 | - | ||
| 2023/3 | 1.78 | 3.48 | -31.31 | 5.44 | -29.82 | 5.44 | 0.31 | - | ||
| 2023/2 | 1.72 | -11.09 | -28.36 | 3.66 | -29.06 | 5.3 | 0.31 | - | ||
| 2023/1 | 1.94 | 17.68 | -29.67 | 1.94 | -29.67 | 5.22 | 0.32 | - | ||
| 2022/12 | 1.64 | 0.53 | -33.23 | 24.76 | -16.84 | 4.89 | 0.72 | - | ||
| 2022/11 | 1.64 | 1.64 | -35.19 | 23.11 | -15.36 | 4.77 | 0.74 | - | ||
| 2022/10 | 1.61 | 5.62 | -38.32 | 21.48 | -13.34 | 4.65 | 0.76 | - | ||
| 2022/9 | 1.52 | 0.2 | -33.34 | 19.87 | -10.4 | 4.58 | 0.31 | - | ||
| 2022/8 | 1.52 | -0.79 | -43.54 | 18.34 | -7.76 | 4.86 | 0.29 | - | ||
| 2022/7 | 1.53 | -15.29 | -41.01 | 16.82 | -2.15 | 7.23 | 0.2 | - | ||
| 2022/6 | 1.81 | -53.51 | -23.01 | 15.29 | 4.75 | 7.54 | 0.29 | - | ||
| 2022/5 | 3.89 | 111.55 | 57.32 | 13.48 | 10.09 | 8.33 | 0.26 | 主要係子公司於今年國內疫情延燒期間積極搶進快篩試劑市場通路佈局，帶動流通事業的業績大幅成長。 | ||
| 2022/4 | 1.84 | -29.01 | -28.5 | 9.59 | -1.87 | 6.83 | 0.32 | - | ||
| 2022/3 | 2.59 | 7.93 | 4.5 | 7.75 | 7.65 | 7.75 | 0.56 | - | ||
| 2022/2 | 2.4 | -12.72 | 5.96 | 5.15 | 9.3 | 7.62 | 0.57 | - | ||
| 2022/1 | 2.75 | 11.72 | 12.4 | 2.75 | 12.4 | 7.74 | 0.56 | - | ||
| 2021/12 | 2.46 | -2.41 | 7.52 | 29.77 | -16.43 | 7.6 | 0.72 | - | ||
| 2021/11 | 2.52 | -3.25 | -19.27 | 27.31 | -18.08 | 7.42 | 0.74 | - | ||
| 2021/10 | 2.61 | 14.14 | -1.15 | 24.78 | -17.95 | 7.59 | 0.72 | - | ||
| 2021/9 | 2.29 | -15.12 | -32.73 | 22.17 | -19.56 | 7.58 | 0.61 | - | ||
| 2021/8 | 2.69 | 3.65 | -26.66 | 19.89 | -17.71 | 7.64 | 0.6 | - | ||
| 2021/7 | 2.6 | 10.56 | -27.02 | 17.19 | -16.11 | 7.42 | 0.62 | - | ||
| 2021/6 | 2.35 | -5.01 | -24.8 | 14.59 | -13.81 | 7.4 | 0.65 | - | ||
| 2021/5 | 2.47 | -3.86 | -12.0 | 12.24 | -11.33 | 7.53 | 0.64 | - | ||
| 2021/4 | 2.57 | 3.75 | -20.37 | 9.77 | -11.16 | 7.32 | 0.66 | - | ||
| 2021/3 | 2.48 | 9.43 | -16.07 | 7.2 | -7.32 | 7.2 | 0.58 | - | ||
| 2021/2 | 2.27 | -7.42 | 14.71 | 4.72 | -1.95 | 7.01 | 0.6 | - | ||
| 2021/1 | 2.45 | 6.87 | -13.57 | 2.45 | -13.57 | 7.87 | 0.53 | - | ||
| 2020/12 | 2.29 | -26.74 | -43.52 | 35.63 | -7.58 | 8.06 | 0.68 | - | ||
| 2020/11 | 3.13 | 18.46 | 1.0 | 33.33 | -3.35 | 9.17 | 0.6 | - | ||
| 2020/10 | 2.64 | -22.31 | -19.15 | 30.21 | -3.78 | 9.71 | 0.56 | - | ||
| 2020/9 | 3.4 | -7.46 | -4.79 | 27.57 | -2.0 | 10.63 | 0.32 | - | ||
| 2020/8 | 3.67 | 3.14 | 5.85 | 24.17 | -1.59 | 10.36 | 0.33 | - | ||
| 2020/7 | 3.56 | 13.91 | 4.59 | 20.5 | -2.82 | 9.5 | 0.36 | - | ||
| 2020/6 | 3.13 | 11.16 | 1.45 | 16.93 | -4.25 | 9.17 | 0.59 | - | ||
| 2020/5 | 2.81 | -13.0 | -11.76 | 13.81 | -5.45 | 9.0 | 0.6 | - | ||
| 2020/4 | 3.23 | 9.36 | 7.02 | 11.0 | -3.69 | 8.16 | 0.66 | - | ||
| 2020/3 | 2.96 | 49.57 | 5.26 | 7.76 | -7.54 | 7.76 | 0.73 | - | ||
| 2020/2 | 1.98 | -30.25 | -12.05 | 4.81 | -13.98 | 8.87 | 0.64 | - | ||
| 2020/1 | 2.83 | -30.16 | -15.27 | 2.83 | -15.27 | 9.99 | 0.57 | - | ||
| 2019/12 | 4.06 | 31.02 | 35.93 | 38.55 | 21.42 | 10.42 | 0.53 | - | ||
| 2019/11 | 3.1 | -5.18 | 18.03 | 34.49 | 19.92 | 9.93 | 0.56 | - | ||
| 2019/10 | 3.27 | -8.51 | 3.36 | 31.4 | 20.11 | 10.3 | 0.54 | - | ||
| 2019/9 | 3.57 | 2.88 | 31.0 | 28.13 | 22.41 | 10.44 | 0.44 | - | ||
| 2019/8 | 3.47 | 1.91 | 31.68 | 24.56 | 21.25 | 9.95 | 0.46 | - | ||
| 2019/7 | 3.4 | 10.49 | 30.0 | 21.09 | 19.7 | 9.67 | 0.48 | - | ||
| 2019/6 | 3.08 | -3.31 | 17.74 | 17.69 | 17.9 | 9.29 | 0.4 | - | ||
| 2019/5 | 3.19 | 5.51 | 22.93 | 14.61 | 17.93 | 0.0 | N/A | - | ||
| 2019/4 | 3.02 | 7.55 | 18.65 | 11.42 | 16.61 | 0.0 | N/A | - |
